AR088235A1 - Derivados de pirazoloquinolina - Google Patents
Derivados de pirazoloquinolinaInfo
- Publication number
- AR088235A1 AR088235A1 ARP120103702A ARP120103702A AR088235A1 AR 088235 A1 AR088235 A1 AR 088235A1 AR P120103702 A ARP120103702 A AR P120103702A AR P120103702 A ARP120103702 A AR P120103702A AR 088235 A1 AR088235 A1 AR 088235A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- optionally
- atoms
- halogen
- atom
- Prior art date
Links
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 abstract 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 2
- -1 3-pyridinyl group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 101100407341 Drosophila melanogaster Pde9 gene Proteins 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229910052731 fluorine Chemical group 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000003551 oxepanyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Exhibe una acción inhibidora de PDE9 y es de utilidad como un agente mejorador de la alteración cognitiva en la enfermedad de Alzheimer. Composición farmacéutica. Reivindicación 1: Un compuesto o su sal farmacéuticamente aceptable representado por la fórmula (1) caracterizado porque R¹ es un átomo de hidrógeno; R² es un grupo de anillo aromático seleccionado del grupo que consiste en un grupo fenilo, un grupo piridinilo y un grupo pirimidinilo, donde los dos átomos en el anillo aromático que es adyacente al átomo de carbono unido al anillo pirazolo[4,3-c]quinolina tienen cada uno, de modo independiente, un sustituyente seleccionado del Grupo A¹ y los otros átomos en el anillo aromático tienen opcionalmente, de modo independiente, un sustituyente seleccionado del Grupo B¹; R³ es un átomo de hidrógeno o un átomo de flúor; R⁴ es un átomo de hidrógeno; R⁵ es un grupo oxepanilo, un grupo dioxepanilo, un grupo tetrahidropiranilo o un grupo tetrahidrofuranilo que tiene opcionalmente un grupo metoxi; R⁶ es un átomo de hidrógeno; Grupo A¹ consiste en un átomo de halógeno, un grupo alquilo C₁₋₆ que tiene opcionalmente 1 a 3 átomos de halógeno y un grupo alcoxi C₁₋₆; y Grupo B¹ consiste en un átomo de halógeno, un grupo ciano, un grupo alquilo C₁₋₆ que tiene opcionalmente 1 a 3 átomos de halógeno, un grupo alcoxi C₁₋₆-alquilo C₁₋₆, un grupo C₁₋₆ alcoxi que tiene opcionalmente 1 a 3 átomos de halógeno y un grupo tetrahidropiranilo, siempre que, cuando R² es un grupo 3-piridinilo, el sustituyente en la posición 4 sea un átomo de halógeno o un grupo alquilo C₁₋₆ que tiene opcionalmente 1 a 3 átomos de halógeno.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161544860P | 2011-10-07 | 2011-10-07 | |
| US201161550623P | 2011-10-24 | 2011-10-24 | |
| US201161558110P | 2011-11-10 | 2011-11-10 | |
| US201161580903P | 2011-12-28 | 2011-12-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088235A1 true AR088235A1 (es) | 2014-05-21 |
Family
ID=48043792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103702A AR088235A1 (es) | 2011-10-07 | 2012-10-04 | Derivados de pirazoloquinolina |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US8563565B2 (es) |
| EP (1) | EP2769980B1 (es) |
| JP (1) | JP5546693B2 (es) |
| KR (1) | KR101943680B1 (es) |
| CN (1) | CN103930423B (es) |
| AR (1) | AR088235A1 (es) |
| AU (1) | AU2012319549B2 (es) |
| BR (1) | BR112014007912B1 (es) |
| CA (1) | CA2861795C (es) |
| CL (1) | CL2014000821A1 (es) |
| CO (1) | CO6910200A2 (es) |
| CY (1) | CY1117427T1 (es) |
| DK (1) | DK2769980T3 (es) |
| ES (1) | ES2568015T3 (es) |
| HR (1) | HRP20160273T1 (es) |
| HU (1) | HUE028555T2 (es) |
| IL (1) | IL231650A (es) |
| IN (1) | IN2014CN02463A (es) |
| JO (1) | JO3116B1 (es) |
| ME (1) | ME02394B (es) |
| MX (1) | MX358149B (es) |
| MY (1) | MY167698A (es) |
| PE (1) | PE20141557A1 (es) |
| PH (1) | PH12014500580A1 (es) |
| PL (1) | PL2769980T3 (es) |
| RS (1) | RS54702B1 (es) |
| RU (1) | RU2605096C2 (es) |
| SG (1) | SG11201400717QA (es) |
| SI (1) | SI2769980T1 (es) |
| SM (1) | SMT201600108B (es) |
| TW (1) | TWI562993B (es) |
| WO (1) | WO2013051639A1 (es) |
| ZA (1) | ZA201402439B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104703987B (zh) | 2011-10-10 | 2017-05-03 | H.隆德贝克有限公司 | 具有咪唑并吡嗪酮骨架的pde9抑制剂 |
| KR102234131B1 (ko) * | 2013-04-05 | 2021-04-01 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 피리디닐피라졸로퀴놀린 화합물 |
| CA2907971C (en) * | 2013-04-05 | 2020-12-29 | Eisai R&D Management Co., Ltd. | Salt of pyrazoloquinoline derivative, and crystal thereof |
| GB201406486D0 (en) | 2014-04-10 | 2014-05-28 | Redx Pharma Ltd | Antibacterial compounds |
| WO2016021192A1 (en) * | 2014-08-08 | 2016-02-11 | Eisai R&D Management Co., Ltd. | Process for production of (s)-(tetrahydrofuran-3-yl)hydrazine |
| MX379456B (es) | 2015-07-07 | 2025-03-10 | H Lundbeck As | Inhibidores de fde9 con estructura básica de imidazotriazinona y estructura básica de imidazopirazinona en el tratamiento de enfermedades periféricas. |
| WO2017046606A1 (en) * | 2015-09-18 | 2017-03-23 | Redx Pharma Plc | Antibacterial compounds |
| CN107056690A (zh) * | 2017-03-22 | 2017-08-18 | 上海康鹏科技有限公司 | 一种6‑溴吡啶‑3‑甲醛的制备方法 |
| MX2019013198A (es) * | 2017-06-01 | 2020-01-20 | Eisai R&D Man Co Ltd | Composicion farmaceutica que comprende un inhibidor de (s)-7-(2metoxi-3,5-dimetilpiridin-4-il)-1-(tetrahidrofuran-3-il)- 1h-pirazolo[4,3-c]quinolin-4(5h)-ona (pde9). |
| KR20200010220A (ko) | 2017-06-01 | 2020-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제 |
| IL270395B (en) | 2017-06-01 | 2022-08-01 | Eisai R&D Man Co Ltd | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil |
| SG11201909590XA (en) * | 2017-06-01 | 2019-11-28 | Eisai R&D Man Co Ltd | Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine |
| US11591312B2 (en) | 2018-01-23 | 2023-02-28 | Basf Se | Halogenation of pyridine derivatives |
| CA3100988A1 (en) | 2018-05-25 | 2019-11-28 | Imara Inc. | Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one |
| WO2020047311A1 (en) | 2018-08-31 | 2020-03-05 | Imara Inc. | Pde9 inhibitors for treating sickle cell disease |
| WO2020120673A1 (en) | 2018-12-13 | 2020-06-18 | Intervet International B.V. | Process for preparing 1-[(3r,4s)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl)amino]p yrazole-4-carboxamide |
| US10919882B2 (en) | 2019-05-09 | 2021-02-16 | The Feinstein Institutes For Medical Research | Compounds for use in synthesis of peptidomimetics |
| WO2020227603A1 (en) | 2019-05-09 | 2020-11-12 | The Feinstein Institutes For Medical Research | Hmgb1 antagonist |
| US11883461B2 (en) | 2019-05-09 | 2024-01-30 | The Feinstein Institutes For Medical Research | HMGB1 antagonist treatment of severe sepsis |
| CA3139104A1 (en) | 2019-05-09 | 2020-11-12 | The Feinstein Institutes For Medical Research | Thiosemicarbazates and uses thereof |
| US11530218B2 (en) | 2020-01-20 | 2022-12-20 | Incyte Corporation | Spiro compounds as inhibitors of KRAS |
| JP7753246B2 (ja) * | 2020-04-16 | 2025-10-14 | インサイト・コーポレイション | 融合三環式ｋｒａｓ阻害剤 |
| US11739102B2 (en) | 2020-05-13 | 2023-08-29 | Incyte Corporation | Fused pyrimidine compounds as KRAS inhibitors |
| CA3188782A1 (en) | 2020-06-30 | 2022-01-06 | Bayer Aktiengesellschaft | Substituted heteroaryloxypyridines, the salts thereof and their use as herbicidal agents |
| US11999752B2 (en) | 2020-08-28 | 2024-06-04 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of KRAS |
| WO2022072783A1 (en) | 2020-10-02 | 2022-04-07 | Incyte Corporation | Bicyclic dione compounds as inhibitors of kras |
| US12077539B2 (en) | 2021-03-22 | 2024-09-03 | Incyte Corporation | Imidazole and triazole KRAS inhibitors |
| EP4367117A1 (en) | 2021-07-07 | 2024-05-15 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
| JP2024534187A (ja) | 2021-08-31 | 2024-09-18 | インサイト・コーポレイション | Ｋｒａｓの阻害剤としてのナフチリジン化合物 |
| US12030883B2 (en) | 2021-09-21 | 2024-07-09 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of KRAS |
| US12030884B2 (en) | 2021-10-01 | 2024-07-09 | Incyte Corporation | Pyrazoloquinoline KRAS inhibitors |
| AU2022367432A1 (en) | 2021-10-14 | 2024-05-02 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2426734C2 (ru) * | 2003-10-03 | 2011-08-20 | Зм Инновейтив Пропертиз Компани | Пиразолопиридины и их аналоги |
| WO2005118583A1 (en) * | 2004-05-28 | 2005-12-15 | Millennium Pharmaceuticals, Inc. | 2, 5-dihydro-pyrazolo`4, 3-c!quinolin-4-ones as chk-1 inhibitors |
| JP5060957B2 (ja) * | 2005-09-15 | 2012-10-31 | あすか製薬株式会社 | 複素環化合物、その製造方法並びに用途 |
| JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
| ES2599054T3 (es) | 2006-12-13 | 2017-01-31 | Aska Pharmaceutical Co., Ltd. | Derivados de quinoxalina |
| DK2152712T3 (da) | 2007-05-11 | 2012-03-26 | Pfizer | Aminoheterocykliske fobindelser |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| MX2011009314A (es) | 2009-03-05 | 2011-10-11 | Astellas Pharma Inc | Compuesto de quinoxalina. |
| WO2010112437A1 (en) | 2009-03-31 | 2010-10-07 | Boehringer Ingelheim International Gmbh | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| US8880976B2 (en) | 2009-09-25 | 2014-11-04 | Stmicroelectronics, Inc. | Method and apparatus for encoding LBA information into the parity of a LDPC system |
| ES2583528T3 (es) * | 2010-09-07 | 2016-09-21 | Astellas Pharma Inc. | Compuesto de pirazoloquinolina |
| JP6042060B2 (ja) * | 2011-09-26 | 2016-12-14 | サノフイ | ピラゾロキノリノン誘導体、その調製および治療上の使用 |
-
2012
- 2012-10-04 ES ES12837953.4T patent/ES2568015T3/es active Active
- 2012-10-04 WO PCT/JP2012/075748 patent/WO2013051639A1/ja not_active Ceased
- 2012-10-04 EP EP12837953.4A patent/EP2769980B1/en active Active
- 2012-10-04 TW TW101136747A patent/TWI562993B/zh active
- 2012-10-04 MX MX2014003800A patent/MX358149B/es active IP Right Grant
- 2012-10-04 CA CA2861795A patent/CA2861795C/en active Active
- 2012-10-04 BR BR112014007912-9A patent/BR112014007912B1/pt active IP Right Grant
- 2012-10-04 US US13/644,745 patent/US8563565B2/en active Active
- 2012-10-04 SG SG11201400717QA patent/SG11201400717QA/en unknown
- 2012-10-04 JP JP2013537544A patent/JP5546693B2/ja active Active
- 2012-10-04 MY MYPI2014700702A patent/MY167698A/en unknown
- 2012-10-04 IN IN2463CHN2014 patent/IN2014CN02463A/en unknown
- 2012-10-04 AU AU2012319549A patent/AU2012319549B2/en active Active
- 2012-10-04 KR KR1020147008769A patent/KR101943680B1/ko active Active
- 2012-10-04 DK DK12837953.4T patent/DK2769980T3/en active
- 2012-10-04 JO JOP/2012/0302A patent/JO3116B1/ar active
- 2012-10-04 PH PH1/2014/500580A patent/PH12014500580A1/en unknown
- 2012-10-04 RU RU2014112931/04A patent/RU2605096C2/ru active
- 2012-10-04 SI SI201230501A patent/SI2769980T1/sl unknown
- 2012-10-04 HU HUE12837953A patent/HUE028555T2/en unknown
- 2012-10-04 AR ARP120103702A patent/AR088235A1/es active IP Right Grant
- 2012-10-04 HR HRP20160273TT patent/HRP20160273T1/hr unknown
- 2012-10-04 ME MEP-2016-65A patent/ME02394B/me unknown
- 2012-10-04 RS RS20160232A patent/RS54702B1/sr unknown
- 2012-10-04 PL PL12837953T patent/PL2769980T3/pl unknown
- 2012-10-04 PE PE2014000408A patent/PE20141557A1/es active IP Right Grant
- 2012-10-04 CN CN201280046653.2A patent/CN103930423B/zh active Active
-
2013
- 2013-06-11 US US13/914,898 patent/US20130296352A1/en not_active Abandoned
-
2014
- 2014-03-19 CO CO14059034A patent/CO6910200A2/es active IP Right Grant
- 2014-03-20 IL IL231650A patent/IL231650A/en active IP Right Grant
- 2014-04-02 ZA ZA2014/02439A patent/ZA201402439B/en unknown
- 2014-04-03 CL CL2014000821A patent/CL2014000821A1/es unknown
-
2016
- 2016-04-12 CY CY20161100302T patent/CY1117427T1/el unknown
- 2016-04-14 SM SM201600108T patent/SMT201600108B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR088235A1 (es) | Derivados de pirazoloquinolina | |
| AR090005A1 (es) | Imidazo[1,2-a]pirimidinas y piridinas sustituidas | |
| AR078609A1 (es) | 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central,tales como depresion y canceres de ovario y renales, entre otros. | |
| MX347917B (es) | Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso. | |
| AR092955A1 (es) | Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona | |
| WO2011156610A3 (en) | Quinoline and isoquinoline derivatives as inhibitors of hepatitis c virus | |
| EA201492204A1 (ru) | Нуклеозиды на основе урацила и спирооксетана | |
| EA201790661A2 (ru) | Ингибиторы вируса гепатита c | |
| EA201491376A1 (ru) | Производные 1h-пирроло[2,3-b]пиридина и их применение в качестве ингибиторов киназы | |
| EA201690848A1 (ru) | Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4 | |
| AR098912A1 (es) | Inhibidores de syk | |
| MX339823B (es) | Ingenol-3-acilatos iii e ingenol-3-carbamatos. | |
| MY186547A (en) | 4?-fluoro-2?-methyl substituted nucleoside derivatives | |
| AR094918A1 (es) | Compuestos de tetrahidropirrolotiazina como inhibidores de bace | |
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
| MY184433A (en) | 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders | |
| IN2012DN01855A (es) | ||
| MX391724B (es) | Nuevos derivados de triazolo[4,5-d]pirimidina. | |
| BR112013021941A2 (pt) | agente terapêutico para tumor | |
| PE20160934A1 (es) | (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolisis | |
| EA201390163A1 (ru) | Гетеробициклические производные в качетстве ингибиторов hcv | |
| HK1211290A1 (en) | Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases | |
| AR094762A1 (es) | Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo | |
| ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
| MX2016007128A (es) | Compuestos del receptor 6 de quimiocina (ccr6). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |